<DOC>
	<DOCNO>NCT02296203</DOCNO>
	<brief_summary>This multicentric , phase II single-arm study KRAS , NRAS BRAF wild-type , irinotecan-resistant metastatic colorectal cancer patient progress initial response first-line cetuximab-containing therapy , receive rechallenge third-line treatment cetuximab plus irinotecan .</brief_summary>
	<brief_title>Cetuximab Rechallenge Irinotecan-pretreated mCRC , KRAS , NRAS BRAF Wild-type Treated 1st Line With Anti-EGFR Therapy ( CRICKET ) .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically proven diagnosis colorectal adenocarcinoma ; RAS BRAF wildtype status ; Firstline irinotecanbased ( FOLFIRI FOLFOXIRI ) cetuximabcontaining therapy produce least partial response ; Firstline progressionfree survival response cetuximabcontaining therapy ≥6 month ; Documentation progression firstline cetuximab within 4 week last cetuximab administration ; Time end firstline therapy start thirdline treatment cetuximab plus irinotecan ≥4 month ; Secondline oxaliplatinbased ( FOLFOXIRI , FOLFOX XELOX ) bevacizumabcontaining therapy ; Documentation progression secondline treatment ; Measurable disease accord RECIST criterion v1.1 ; Have tumor tissue ( primary tumor metastasis least one two ) available biomarker analysis ; Male female patient &gt; 18 year age ; ECOG Performance Status ≤ 2 ; Life expectancy least 3 month ; Adequate bone marrow , liver renal function assess within 14 day start study treatment ; Women childbearing potential must negative blood pregnancy test baseline visit . For trial , woman childbearing potential defined woman puberty , unless postmenopausal least 12 month , surgically sterile sexually inactive ; Subjects partner must willing avoid pregnancy trial 6 month last trial treatment . Male subject female partner childbearing potential female subject childbearing potential must , therefore , willing use adequate contraception approve investigator , twobarrier method onebarrier method spermicidal intrauterine device . This requirement begin 2 week receive first trial treatment end 6 month receive last treatment ; Signed informed consent obtain study specific procedure . Active uncontrolled infection active disseminate intravascular coagulation ; Past current history malignancy colorectal carcinoma , except curatively treat basal squamous cell carcinoma skin cancer situ carcinoma cervix ; Fertile woman ( &lt; 12 month last menstruation ) men childbearing potential willing use effective mean contraception Women pregnant breastfeeding ; Previous grade 3/4 infusion relate reaction cetuximab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>cetuximab rechallenge</keyword>
</DOC>